Reversing the Psychiatric Effects of Neurodevelopmental Cannabinoid Exposure: Exploring Pharmacotherapeutic Interventions for Symptom Improvement
Neurodevelopmental exposure to psychoactive compounds in cannabis, specifically THC, is associated with a variety of long-term psychopathological outcomes. This increased risk includes a higher prevalence of schizophrenia, mood and anxiety disorders, and cognitive impairments. Clinical and pre-clini...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/15/7861 |
| _version_ | 1797525601080311808 |
|---|---|
| author | Marta De Felice Steven R. Laviolette |
| author_facet | Marta De Felice Steven R. Laviolette |
| author_sort | Marta De Felice |
| collection | DOAJ |
| description | Neurodevelopmental exposure to psychoactive compounds in cannabis, specifically THC, is associated with a variety of long-term psychopathological outcomes. This increased risk includes a higher prevalence of schizophrenia, mood and anxiety disorders, and cognitive impairments. Clinical and pre-clinical research continues to identify a wide array of underlying neuropathophysiological sequelae and mechanisms that may underlie THC-related psychiatric risk vulnerability, particularly following adolescent cannabis exposure. A common theme among these studies is the ability of developmental THC exposure to induce long-term adaptations in the mesocorticolimbic system which resemble pathological endophenotypes associated with these disorders. This narrative review will summarize recent clinical and pre-clinical evidence that has elucidated these THC-induced developmental risk factors and examine how specific pharmacotherapeutic interventions may serve to reverse or perhaps prevent these cannabis-related risk outcomes. |
| first_indexed | 2024-03-10T09:15:14Z |
| format | Article |
| id | doaj.art-b152a571ffa64655956145b566ba19e9 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T09:15:14Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-b152a571ffa64655956145b566ba19e92023-11-22T05:39:33ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-07-012215786110.3390/ijms22157861Reversing the Psychiatric Effects of Neurodevelopmental Cannabinoid Exposure: Exploring Pharmacotherapeutic Interventions for Symptom ImprovementMarta De Felice0Steven R. Laviolette1Addiction Research Group, Department of Anatomy and Cell Biology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON N6A 5C1, CanadaAddiction Research Group, Department of Anatomy and Cell Biology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON N6A 5C1, CanadaNeurodevelopmental exposure to psychoactive compounds in cannabis, specifically THC, is associated with a variety of long-term psychopathological outcomes. This increased risk includes a higher prevalence of schizophrenia, mood and anxiety disorders, and cognitive impairments. Clinical and pre-clinical research continues to identify a wide array of underlying neuropathophysiological sequelae and mechanisms that may underlie THC-related psychiatric risk vulnerability, particularly following adolescent cannabis exposure. A common theme among these studies is the ability of developmental THC exposure to induce long-term adaptations in the mesocorticolimbic system which resemble pathological endophenotypes associated with these disorders. This narrative review will summarize recent clinical and pre-clinical evidence that has elucidated these THC-induced developmental risk factors and examine how specific pharmacotherapeutic interventions may serve to reverse or perhaps prevent these cannabis-related risk outcomes.https://www.mdpi.com/1422-0067/22/15/7861cannabismarijuanaTHCendocannabinoid systemadolescenceneurodevelopment |
| spellingShingle | Marta De Felice Steven R. Laviolette Reversing the Psychiatric Effects of Neurodevelopmental Cannabinoid Exposure: Exploring Pharmacotherapeutic Interventions for Symptom Improvement International Journal of Molecular Sciences cannabis marijuana THC endocannabinoid system adolescence neurodevelopment |
| title | Reversing the Psychiatric Effects of Neurodevelopmental Cannabinoid Exposure: Exploring Pharmacotherapeutic Interventions for Symptom Improvement |
| title_full | Reversing the Psychiatric Effects of Neurodevelopmental Cannabinoid Exposure: Exploring Pharmacotherapeutic Interventions for Symptom Improvement |
| title_fullStr | Reversing the Psychiatric Effects of Neurodevelopmental Cannabinoid Exposure: Exploring Pharmacotherapeutic Interventions for Symptom Improvement |
| title_full_unstemmed | Reversing the Psychiatric Effects of Neurodevelopmental Cannabinoid Exposure: Exploring Pharmacotherapeutic Interventions for Symptom Improvement |
| title_short | Reversing the Psychiatric Effects of Neurodevelopmental Cannabinoid Exposure: Exploring Pharmacotherapeutic Interventions for Symptom Improvement |
| title_sort | reversing the psychiatric effects of neurodevelopmental cannabinoid exposure exploring pharmacotherapeutic interventions for symptom improvement |
| topic | cannabis marijuana THC endocannabinoid system adolescence neurodevelopment |
| url | https://www.mdpi.com/1422-0067/22/15/7861 |
| work_keys_str_mv | AT martadefelice reversingthepsychiatriceffectsofneurodevelopmentalcannabinoidexposureexploringpharmacotherapeuticinterventionsforsymptomimprovement AT stevenrlaviolette reversingthepsychiatriceffectsofneurodevelopmentalcannabinoidexposureexploringpharmacotherapeuticinterventionsforsymptomimprovement |